• Clinical Trials
  • Patients and Caregivers
  • Healthcare Professionals
  • Investors and Media
  • Careers

  • Who We Are
    • Executive Committee Our History
  • What We Do
    • Our Science Our Target Indications Our Pipeline Our Products Publications
  • Who We Are
    • Overview
    • Executive Committee
    • Our History
  • What We Do
    • Overview
    • Our Science
    • Our Target Indications
    • Our Pipeline
    • Publications
  • How We Do It
    • Overview
    • Our Culture
    • Careers
  • Patients and Caregivers
  • Healthcare Professionals
  • Investors and Media
  • Careers

Initial Safety and Activity Findings from a Phase IB Escalation Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC) in Combination with Pembrolizumab in Platinum-Resistant Epithelial Ovarian Cancer Patients

  • Contact Us
  • Privacy Notice
  • Consumer Health Data Privacy Notice
  • Cookies Settings
  • Your Privacy Choices privacy
  • Usage Policy

© 2024 ImmunoGen, Inc., All Rights Reserved

ImmunoGen, the ImmunoGen logos, and TARGET A BETTER NOW are trademarks or registered trademarks of ImmunoGen, Inc.

IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.